ROIV
Roivant Sciences Ltd.
October 8, 2026 · pre-market
- Rarity
- 1.31
- Peak move
- −5.06%
- Float cap
- $18.0B
Roivant Sciences Ltd. is a biopharmaceutical company that develops and commercializes medicines for patients with unmet medical needs. It advances a pipeline of investigational therapies, including brepocitinib, IMVT-1402, and mosliciguat, through nimble subsidiaries called Vants. The company also incubates discovery-stage biopharmaceutical and health technology startups complementary to its core business.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
5 events · 0 from SEC or newswire · 0 timed with the moveanalyst_ratingMarketBeat reported that Roivant Sciences has a 'Moderate Buy' consensus rating from 13 analysts, with an average 12-month price target of $45.64.
insider_saleRoivant Sciences CEO Eric Venker sold 200,000 shares at an average price of $36.62, a $7.32 million transaction dated Sept 30, 2026 under a Rule 10b5-1 plan.
institutional_flowInstitutional holders including Assenagon Asset Management, Perceptive Advisors, Baker Bros and Wellington Management increased their positions in Roivant Sciences, which is 64.76% institutionally owned.
institutional_flowRoivant Sciences tendered 8,967,383 Arbutus Biopharma common shares at $5.00 in Arbutus's modified Dutch auction tender offer, receiving about $44,836,915, and retains 29,880,079 shares (~19.5% of Arbutus).
insider_saleRoivant Sciences director Melissa B. Epperly sold 17,750 shares at weighted average prices of $36.08 and $36.57 on Oct 1, 2026, after exercising 17,750 options at $4.46 under a Rule 10b5-1 plan.